To include your compound in the COVID-19 Resource Center, submit it here.

Proacta, Yakult deal

The partners expanded a February deal to give Yakult Honsha exclusive rights to cancer candidate PR610 in Japan. The partners

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE